MedWatch

Bavarian still struggles with the repercussions of Prostvac failure

Bavarian Nordic's scars are still not completely healed after the failure in phase III with the prostate cancer vaccine, Prostvac, about two years ago. However, CEO Paul Chaplin maintains that Bavarian will become a successful company.

When Danish company Bavarian Nordic recently presented its quarterly results, CEO Paul Chaplin was in an excellent mood. 

And he has several reasons to smile because currently, Bavarian follows the company's strategy and guidance more or less completely.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier